Vice President of Clinical Operations
Julie brings more than 25 years of experience guiding clinical development programs through the U.S. Food and Drug Administration clearance process. Previously, Julie served as executive director, clinical operations at Kodiak Sciences Inc., a now-public clinical biopharmaceutical company. Prior to Kodiak, she served as executive director of clinical development at Laguna and, prior to that, at Sorbent Therapeutics. Prior to Sorbent, Iwashita was senior director of clinical development at MAP Pharmaceuticals and held positions at Proteolix, through its acquisition by Onyx Pharmaceuticals, and at Affymax. She has also managed clinical programs at Genitope, Aviron (through acquisition by MedImmune), Amgen and Syntex in various therapeutic areas including renal, cardiovascular, and oncology. Julie holds a bachelor’s degree in human biology from Stanford University.